基于纳米生物技术的血液替代品。
Blood substitutes based on nanobiotechnology.
作者信息
Chang Thomas Ming Swi
机构信息
Department of Physiology, Faculty of Medicine, McGill University, 3655 Drummond Street, Montreal, Quebec, H3G 1Y6, Canada.
出版信息
Trends Biotechnol. 2006 Aug;24(8):372-7. doi: 10.1016/j.tibtech.2006.06.005. Epub 2006 Jul 11.
Stimulated by concerns of potential infective agents in donated blood, commercial enterprises have attempted to develop blood substitutes since the 1900s. After several years of development, a few of the many leads are showing promise. In this article, nanobiotechnological approaches that are now in phase III clinical trials are reviewed, followed by a discussion of how important basic knowledge gained is being used to develop new generations of blood substitutes based on nanobiotechnology.
受对献血中潜在传染源担忧的刺激，自20世纪以来，商业企业就试图开发血液替代品。经过数年发展，众多研发方向中有一些已展现出前景。本文回顾了目前正处于III期临床试验阶段的纳米生物技术方法，随后讨论了如何利用所获得的重要基础知识来开发基于纳米生物技术的新一代血液替代品。
Zotero 插件